Hostname: page-component-6898cfcb55-cbk24 Total loading time: 0 Render date: 2026-11-11T11:39:24.831Z Has data issue: false hasContentIssue false
  • English
  • Français

Subjective well-being with antipsychotic treatment

Published online by Cambridge University Press:  24 June 2014

R. Köhler,
Jiri Masopust and
Jan Libiger
R. Köhler
Affiliation:
Charles University in Prague, Faculty of Medicine in Hradec Králové, and University Hospital Hradec Králové, Department of Psychiatry, Hradec Králové, Czech Republic
Jiri Masopust
Affiliation:
Charles University in Prague, Faculty of Medicine in Hradec Králové, and University Hospital Hradec Králové, Department of Psychiatry, Hradec Králové, Czech Republic
Jan Libiger
Affiliation:
Charles University in Prague, Faculty of Medicine in Hradec Králové, and University Hospital Hradec Králové, Department of Psychiatry, Hradec Králové, Czech Republic
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.

Information

Type
Inpc Young Psychiatrists Programme
Information
Acta Neuropsychiatrica , Volume 21 , Issue S2: Special Issue: Abstracts of 49th Neuropsychiatric Pula Congress, 17-20 June 2009, Pula, Croatia , June 2009, pp. 65
Copyright
Copyright © 2009 John Wiley & Sons A/S

Objectives:

The factors that influence compliance with antipsychotic treatment in schizophrenia are related to the patient, the patient's environment, the attending physician, and the treatment itself Reference Fleischhacker and Oehl(2)). Important causes of nonadherence are adverse effects (AEs) of antipsychotics. Initial dysphoric reaction, extrapyramidal symptoms, akathisia, sexual dysfunction and obesity belong to the most frequent AEs Reference Awad and Voruganti(1,Reference Fleischhacker and Oehl2,Reference Libiger5,Reference Švestka and Bitter8,Reference Van Putten and May9). The patient's subjective well-being and attitude toward antipsychotic medication are considered important for compliance Reference Švestka and Bitter(8,Reference Van Putten and May10).

Methods:

Severity of symptoms was estimated using the PANSS (Positive and Negative Symptoms of Schizophrenia) and CGI (Clinical Global Impression) scales. Self-rating Subjective Well-being under Neuroleptic scale (SWN) was applied to evaluate the patients' subjective well-being Reference Naber and Karow(6,Reference Naber7). We also administered the Drug Attitude Inventory (DAI) scale to evaluate the attitude of the study subjects toward antipsychotic medication Reference Hogan and Awad(3,Reference Hogan and Awad4).

Results:

Seventy-five outpatients (women n = 25) at the mean age of 34.6 years (median 32 years) with the diagnosis of schizophrenia were included into the study. The patients with the most pronounced subjective well-being were in remission, treated with monotherapy, and low doses of antipsychotic drugs.

Conclusion:

Subjective well-being is increasingly being accepted as a valid and important measure of antipsychotic treatment outcomes and tolerability. Meaningful way of antipsychotic treatment with minimal AEs can increase the patient's subjective well-being and compliance.

References

References:

1.Awad, AG, Voruganti, LN.Neuroleptic dysphoria: revisiting the concept 50 years later. Acta Psychiatr Scand Suppl 2005;427:6–13.CrossRefGoogle Scholar
2.Fleischhacker, WW, Oehl, MAet al.Factors influencing compliance in schizophrenia patients. J Clin Psychiatry 2003;64(Suppl. 16):10–13.Google ScholarPubMed
3.Hogan, TP, Awad, AGet al.A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983;13:177–183.CrossRefGoogle ScholarPubMed
4.Hogan, TP, Awad, AG.Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychol Med 1992;22:347–352.CrossRefGoogle ScholarPubMed
5.Libiger, J. Neuroleptická dysforie v éře antipsychotik: nové otázky. Psychiatrie 2004;8(Suppl. 1):25.Google Scholar
6.Naber, D, Karow, Aet al.Subjective well-being under neuroleptic treatment and its relevance for compliance. Acta Psychiatricac Scand Suppl 2005;427:29–34.CrossRefGoogle Scholar
7.Naber, D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 1995;10(Suppl. 3):133–138.Google ScholarPubMed
8.Švestka, J, Bitter, I.Nonadherence to antipsychotic treatment in patients with schizophrenic disorders. Neuroendocrinol Lett 2007;28(Suppl. 1):95–116.Google ScholarPubMed
9.Van Putten, T, May, PRAet al.Subjective response to antipsychotic drugs. Arch Gen Psychiatry 1981;38:187–190.CrossRefGoogle ScholarPubMed
10.Van Putten, T, May, PRAet al.Akathisia with haloperidol and thiothixene. Arch gen Psychiatry 1984;41:1036–1039.CrossRefGoogle ScholarPubMed